Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (TheStreet) -- CHANGE IN RATINGS, EPS
CIT Group (CIT) estimates lowered at Sterne Agee CIT estimates lowered through 2011. Incorporating debt repayments. Maintain $50 price target and Buy rating.
Clean Harbors (CLH) upgraded at JP Morgan from Neutral to Overweight. $70 price target. Stock is attractive, following a 13% pullback.Cree (CREE) downgraded at Wunderlich from Hold to Sell. $25 price target. The weakness is global chip bookings could soon accelerate. Dendreon (DNDN) target cut at ThinkEquity to $21. Pricing in full restructuring costs. Buy rating. Diamond Foods (DMND) target raised at KeyBanc to $85. Ongoing investments in advertising and new products. Buy rating. Ecolab (ECL) target raised at Citigroup to $57. Solid product pipeline and good progress on EMEA restructuring. Buy rating. The Hartford (HIG) estimates, target lowered at UBS. Shares of HIG now seen reaching $38. Estimates also cut on likely large 3Q11 deferred acquisition costs. Buy rating. Hill-Rom (NYT) rated new Overweight at Morgan Stanley. $37 price target. Company can deliver consistent growth over the coming years. Kroger (KR) estimates, target lowered at Jefferies. Shares of KR now seen reaching $26. Estimates also lowered on flat volumes. Buy rating. Lululemon (LULU) estimates, target increased at Credit Suisse. LULU estimates were raised through 2014. Higher sales is driving wider margins. Neutral rating and new $59 price target. Lululemon estimates, target increased at Jefferies. Shares of LULU now seen reaching $59. Estimates also raised on continued global strength in market demand. Hold rating. McDonalds (MCD) estimates, target cut at UBS. Shares of MCD now seen reaching $96. Estimates also lowered following weaker than expected August SSS. Buy rating. Mosaic (MOS) upgraded at Goldman to Buy. Company is leveraged to an improving supply/demand outlook. Myriad Genetics (MYGN) upgraded at Auriga from Hold to Buy. $24 price target. Company can deliver solid growth in 2012. New York Times (NYT) estimates, target lowered at UBS. Shares of NYT now seen reaching $8. Estimates also lowered on apparent slowing in September. Neutral rating. Oracle (ORCL) added to Conviction Buy List at Goldman. Pullback has created an attractive buying opportunity. $33 price target.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV